Stevanato Group S.p.A.
STVNStevanato Group S.p.A. (STVN) is an Italian company specializing in the design, manufacturing, and distribution of drug containment and delivery systems. It provides glass primary packaging, auto-injectors, and related technologies for the pharmaceutical and biotech industries, supporting the safe and effective delivery of medications globally.
Dividend History
Investors can expect a dividend payout of $0.05 per share, scheduled to be distributed in 11 days on July 29, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 29, 2026 | $0.05 | 2026-06-11 | 2026-06-11 |
| July 17, 2025 | $0.05 | 2025-06-05 | 2025-06-05 |
| July 15, 2024 | $0.05 | 2024-06-04 | 2024-06-04 |
| July 17, 2023 | $0.05 | 2023-06-07 | 2023-06-06 |
| July 13, 2022 | $0.05 | 2022-06-13 | 2022-06-14 |
Dividends Summary
- Consistent Payer: Stevanato Group S.p.A. has rewarded shareholders with 5 dividend payments over the past 4 years.
- Total Returned Value: Investors who held STVN shares during this period received a total of $0.27 per share in dividend income.
- Latest Payout: The most recent dividend of $0.05/share was paid 366 days ago, on July 17, 2025.
- Yield & Schedule: STVN currently pays dividends yearly with an annual yield of 0.28%.
- Dividend Growth: Since 2022, the dividend payout has grown by 5.9%, from $0.05 to $0.05.
Company News
The global pharmaceutical glass packaging market is projected to grow from USD 5.32 billion in 2025 to USD 12.39 billion by 2035, with a CAGR of 8.82%. Growth is driven by rising demand for injectables, biologics, and GLP-1 therapies, alongside stringent EU regulatory requirements for sustainability and anti-counterfeiting measures. Europe, parti...
The European market for glass prefilled syringes and glass vials packaging equipment is projected to grow from USD 283.30 billion in 2025 to USD 389.13 billion by 2034, driven by rising demand for injectable biologics, sterile drug delivery systems, and advanced healthcare infrastructure.
The global prefilled syringes market is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection. The market is expected to reach USD 28 billion by 2032, with North America leading the growth.
The global dual chamber prefilled syringes market is expected to grow at a CAGR of 9.0% from 2024 to 2034, driven by the increased demand for biologics and biosimilars. The market is projected to reach a valuation of US$ 5,495.5 million by 2034.
USNA vs. STVN: Which Stock Is the Better Value Option?
Related Companies
